The shares of ImmunoGen soared at the open today after the company disclosed favorable findings from its ovarian cancer study of mirvetuximab soravtansine.
With a validated objective response rate of 32.4%, the SORAYA trial accomplished its primary aim.
ImmunoGen's stock is currently up more than 37%.
The firm plans to submit a Biologics License Application for mirvetuximab, a potential treatment for platinum-resistant ovarian cancer, to the Food and Drug Administration for accelerated clearance in the first quarter of 2022, according to the company.
The results of the SORAYA trial "further validate our longstanding history of innovation in ADCs," according to Mark Enyedy, ImmunoGen's president and CEO.
"Commercial preparations are well underway to support the potential launch of mirvetuximab next year," he added.
In the first quarter of 2022, the administration will seek accelerated approval.